Efficacy of Suvorexant on Post-operative Sleep Disturbance
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The study is a parallel group, double blind, randomized trial. Subjects will be recruited
from individuals undergoing elective surgery for orthopedic, abdominal, urologic, gynecologic
or spine reasons. Out of 92 subjects, one experimental group of 46 subjects will receive 20
mg Suvorexant beginning the first in-hospital night ("day 0") and continuing for their
hospital stay. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose
may be decreased to 10 mg of Suvorexant.
For blinding purposes each arm will receive two tablets (two 10 mg tablets or one 10 mg
tablet and a placebo). The other control group of 46 subjects will receive placebo (two
tablets) and treatment as usual.